Expensive Medicines

Why It Matters

Escalating drug costs threaten to push millions of Filipinos into poverty and strain an already aging healthcare system, highlighting urgent need for regulatory reform.

Key Takeaways

• Up to 273% price inflation before tax on medicines.
• Retailers capture 40‑60% of drug cost, not manufacturers.
• One pharmacy chain controls ~80% of retail sales.
• Out‑of‑pocket health spend hit ₱615 bn (~$11 bn) in 2024.
• Bulk purchasing and government negotiation could cut prices dramatically.

Pulse Analysis

The Philippine drug market’s price explosion stems from a tightly‑controlled supply chain where a single retailer chain and a dominant wholesaler command the majority of sales. Their layered mark‑ups—often exceeding 200% before taxes—turn generic imports that cost a fraction abroad into costly retail products. This concentration creates a de‑facto cartel, allowing each intermediary to capture a sizable profit slice while the government’s price‑control mechanisms are effectively bypassed. The result is a system where patients shoulder the bulk of costs, and any negotiated savings evaporate before reaching the consumer.

For an aging society already grappling with limited pension benefits, these inflated prices are more than an inconvenience—they are a barrier to essential care. A 2019 Pulse Asia survey cited in House Bill 5956 revealed that 99% of Filipinos skip prescribed medicines due to cost, a figure echoed by a PubMed study showing half of out‑of‑pocket health expenses go to drugs. Compared with neighboring ASEAN nations and Canada’s centrally‑negotiated pricing, the Philippines’ out‑of‑pocket burden is stark, contributing to a growing risk of medical‑induced poverty among the middle class.

Policy experts argue that bulk purchasing, transparent pricing, and a proactive government negotiating body could dramatically lower costs. Successful models in Canada and the EU show that setting price ceilings and consolidating demand can shave off 30‑50% of drug prices. However, entrenched interests within the drug‑retail cartel and a passive Competition Commission impede reform. Strengthening antitrust enforcement, mandating price‑transparency, and empowering a national procurement agency are critical steps to dismantle the current pricing hierarchy and ensure affordable access for all Filipinos.